Medication Treatments

NCAD West: Streamlined Medication Unit Brings Treatment to Rural Communities
Community Medical Services regional operations manager Haley Horton explained to NCAD West attendees how the organization has engaged patients in remote areas through the development of medication units as a complement to its traditional opioid treatment programs.
Company Working Toward Once-Yearly Naltrexone Product
A life sciences company that is testing a sustained-release risperidone product for psychosis is now pursuing an effort to improve adherence to naltrexone for opioid dependence.
NCAD Spotlight: Fentanyl Driving Abstinence-Based Treatment Programs to Consider MAT
With fentanyl driving up overdose-related death rates among patients who relapse, formerly abstinence-based treatment programs are beginning to embrace medication-assisted treatment, says Andrew Stone, MD, MPH.
Research Bolsters Hazelden Betty Ford's Embrace of MAT
Initial research is helping to confirm Hazelden Betty Ford Foundation's move to established focused treatment for opioid addiction that includes extended medication treatment.
Supportive Care Essential to Maximize Effectiveness of Buprenorphine for Opioid Addiction
SAN DIEGO—Medication treatments such as buprenorphine can make a difference for patients with opioid addiction if they are part of a comprehensive care plan, Arwen Podesta, MD, said at Psych Congress 2019.
NCAD West: Prescription Opioid Misuse Drops, but Providers Need to Stay Vocal
During the opening plenary of NCAD West on Thursday, Colorado Consortium for Prescription Drug Abuse director Rober Valuck, PhD, RPh, FNAP, implored attendees to aggressively fight barriers to treatment, scrutinize their own work, and learn from their peers.
NCAD West: Focus on Function When Treating Chronic Pain
Las Vegas Recovery Center chief medical officer Mel Pohl, MD, DFASAM, shared risks of using opioids to treat chronic pain and offered non-medication alternatives to improve patients’ ability to function on Thursday at NCAD West.
Lofexidine Demonstrates Efficacy During Early Opioid Withdrawal
SAN DIEGO—The opioid withdrawal drug lofexidine demonstrated statistically significant efficacy across a half-dozen patient- and clinician-reported outcomes during the first 7 days after immediate opioid cessation, according to study presented at…
Robust Treatment Options Remain Limited for Stimulant Use Disorder
SAN DIEGO—Prescribers who may be seeing an increase in patients with stimulant use disorders are still left relying on off-label treatment options with limited evidence of effectiveness, a researcher told a Psych Congress audience.
Managing Patients With Opioid Use Disorder and Chronic Pain
SAN DIEGO—Mental health clinicians will likely be taking on many more patients with opioid use disorder, as 40% of primary care providers will not accept any new patients who take opioids, an expert said at Psych Congress 2019.
CDC Researcher: Stick with FDA-Approved Meds Over E-Cigarettes for Smoking Cessation
E-cigarettes can be considered “safer” than traditional cigarettes, but a lack of research around their long-term use should prevent them from being considered “safe” in general, CDC Office on Smoking and Health deputy director of research Brian King, PhD, MPH said.
Back to Top